Home About Us Writing a Scientific Article Author's Instruction Contact us



/  /    MRJMMS Home   /   /    About MRJMMS    /  /    Submit Manuscripts    /  /      Call For Articles      / /     Editorial Board     / /    Archive     / /    Author's Guide  /  /


March 2017 Vol. 5 No.3

Other viewing option

• Full text
Reprint (PDF) (292 KB)

Search Pubmed for articles by:

Aboelhassan R

Other links:
PubMed Citation
Related articles in PubMed



Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 5(3) pp. 126-129, March, 2017 

Copyright © 2017 Merit Research Journals

Case Report

Outcome of switching antiangiogenic therapies in combination with FOLFRI as a treatment beyond second line for mutant K- RAS metastatic
colorectal cancer


Dr. Rasha Aboelhassan


Nasser Institute Cancer Center- EGYPT

E-mail: elsayedonco@hotmail.com

Accepted February 09, 2017




Anti-angiogenesis targeted therapy in combination with chemotherapy is one of the limited options for systemic therapy beyond second line for patient with Ras mutant metastatic colorectal cancer. Aflibercept is an antiangiogenic therapy which improved survival for metastatic colorectal cancer with FOLFRI as a second line after failure of oxaliplatin containing regimen and can be used after failure of use of FOLFOX, or after failure of chemotherapy combination with bevacizumab, other options of antiangiogenic therapies include regorafenib or bevacizumab beyond disease progression. In this case report, the patient is a 53 years old male who had a multiple line of therapies for metastatic colorectal cancer (mCRC), including bevacizumab in combination with FOLFRI. He had complete remission confirmed by PET-CT after 6th cycle of aflibercept in combination with FOLFRI and reached progression free survival of eleven months. Aflibercept in combination with FOLFRI can give adequate Progression Free Survival (PFS) as a treatment beyond second line for good responder patients. This finding needs further research work and investigations.

Keywords: Aflibercept, Antiangiogenic therapy, mCRC, treatment beyond second line






Merit Research Journals© 2017 || Advertisement | Privacy policy.